Oncology & Hematology

Our ultimate vision is to prevent and provide cures for cancer in all its forms. Recognizing that no single intervention can achieve this comprehensive goal, we strive to deeply understand the disease, its complexities, and its impact on patients.

We are proud to have the broadest and most diverse pipeline in oncology, with more than 20 immunotherapy molecules currently in development. Since 2011, we have introduced 18 oncology medicines. Our efforts are united by a commitment to exploring therapeutic combinations and pursuing personalized medicines.

Reflecting our pharma strategy, we aim to bolster end-to-end investment in key disease areas (lung cancer, breast cancer, and malignant haematological conditions), while continually seeking transformative medicines in other areas. This integrated approach ensures that we address the full spectrum of patient needs, from prevention and diagnosis to treatment and beyond.

Partnering opportunities we are looking for:

Tumor types

• Breast
• Lung
• Malignant haematology (including multiple myeloma (MM), lymphoma, acute myeloid leukemia (AML))
• Transformative therapies in other indications - notably including colorectal cancer (CRC), prostate, bladder

Pathways/modalities

• Oncogenic drivers
• Cancer cell dependencies
• Antibody Drug Conjugates (ADCs)
• Cancer immunotherapy - including TCEs, bispecifics, innate and stromal cell
• Allogeneic cell therapies

Example partnerships

AbbVie - Co-research, co-development and co-commercialization collaboration focused on Venclexta.

BioNTech – Collaboration to develop individualized mRNA cancer vaccines.

Caris Life Sciences – Research collaboration and license agreement to identify and validate novel oncology targets in solid tumor tissue.

Hansoh Pharma – License agreement for a novel CDH17-targeting antibody drug conjugate (ADC).

MediLink Therapeutics – Collaboration and license agreement to develop next generation antibody drug conjugate candidate targeting c-Mesenchymal epithelial transition factor against solid tumors.

Orionis Biosciences – Collaboration to discover small-molecule monovalent glue medicines for novel and challenging targets in oncology.

Poseida Therapeutics Acquisition to augment our efforts to bring transformative medicines to patients across Oncology, Immunology and Neurology.

Regor Pharmaceuticals – Acquisition of Regor’s next-generation CDK inhibitors for the treatment of breast cancer.

Starpharma - Collaboration and license agreement to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets.

Explore collaboration opportunities

Connect with our partnering experts to start the conversation.